Commentary on ‘Prognostic factors for acute vertebrobasilar artery occlusion-reperfusion: a multicenter retrospective cohort study’

Jinping Zhang, Haitao Li, Zunlu Zhang, Mingzhe Hu, Bingchen LiInternational Journal of Surgery 2024 · DOI

TL;DR

This commentary discusses a recent study on prognostic factors for acute vertebrobasilar artery occlusion (VBAO) treated with endovascular therapy (EVT). It highlights that while EVT is becoming the standard of care for VBAO, more robust evidence, particularly from large prospective randomized controlled trials, is needed to fully understand its long-term prognostic variables and optimize treatment strategies.

What Problem Does This Paper Address?

The paper addresses the critical need for better understanding and prediction of outcomes for patients experiencing acute vertebrobasilar artery occlusion (VBAO). VBAO is a severe type of stroke with a high mortality rate and significant disability. While endovascular treatment (EVT) is increasingly used and shows promise, there's a lack of comprehensive data, especially from randomized controlled trials, to definitively establish its long-term prognostic factors. This gap makes it challenging to optimize patient selection and treatment strategies for the best possible outcomes.

Methods

This is a commentary on a previously published retrospective cohort study. Therefore, the methods described are those of the original study by Huang et al. [1]. The original study was a multicenter retrospective cohort study that analyzed patients with acute, symptomatic, radiologically confirmed VBAO treated with EVT. The purpose was to examine long-term prognostic variables for these patients.

Datasets

Not discussed in the paper. The commentary refers to a multicenter retrospective cohort study, implying data was collected from multiple institutions, but specific dataset details are not provided.

Key Insights and Ideas

  • EVT is the emerging standard: Despite historical skepticism from some randomized trials, current evidence suggests EVT is a viable and effective treatment for VBAO, becoming the primary approach for many patients.
  • Need for stronger evidence: While the reviewed study provides valuable insights, the commentary emphasizes the limitations of retrospective data. The authors call for large-scale prospective randomized controlled trials to solidify understanding of long-term prognostic factors.
  • Challenges in multicenter studies: The commentary points out inherent challenges in multicenter retrospective studies, such as variations in patient selection criteria, imaging protocols, and thrombectomy approaches across different centers, which can introduce variability and potential confounding factors.
  • Gender disparities in stroke: The commentary briefly notes that gender disparities in stroke incidence, presentation, treatment, and prognosis are a significant area of ongoing research.

Key Results

Not discussed in the paper. As this is a commentary, it focuses on discussing the implications and limitations of another study rather than presenting its own quantitative results.

Limitations and Future Work

The commentary highlights several limitations of the original study and suggests future directions:

  • Retrospective design: The original study was retrospective, which inherently has limitations compared to prospective designs.
  • Multicenter variability: Differences in patient selection, imaging, and procedural techniques across the 21 participating centers could influence results.
  • Potential for missed confounding factors: The retrospective nature may lead to unaddressed confounding variables.
  • Future Work: The authors strongly advocate for large-sample size prospective multicenter randomized controlled trials to more thoroughly evaluate long-term prognostic variables in VBAO patients treated with EVT. They also suggest that subgroup analysis and long-term follow-up will be crucial as more cases become available.

Summary updated

Abstract

Huang et al. [1] conducted a multicenter retrospective cohort study on patients with an acute, symptomatic, radiologically confirmed acute vertebrobasilar artery occlusion (VBAO) who were treated with endovascular treatment (EVT).Research suggests that unique risk assessment combined with optimization for EVT may enhance long-term prognosis.VBAO, which causes 1% of all strokes and 5% of major vascular occlusions, is a catastrophic neurological condition with high mortality and severe disability [2] .Its natural history reveals a mortality rate of up to 90% and a significant residual deficit in 65% of patients who do not receive treatment [3] .EVT is now thought to be a viable therapeutic method for acute basilar artery occlusion (ABAO), since standard medical treatment (SMT) alone is linked to low recanalization rates and unfavorable outcomes in patients with ABAO [4] .Since 2006, a number of studies have examined the safety and effectiveness of EVT in individuals with ABAO.The findings of this research indicate that EVT may be linked to improvements in clinical outcomes that are both safe and effective as well as a reduction in patient mortality.Despite being the gold standard treatment for patients with proximal arterial occlusion and anterior circulation acute ischemic stroke, there is currently a dearth of data from randomized clinical trials evaluating the efficacy of EVT for ABAO.It was established by earlier, sizable randomized controlled trials that EVT was not better than conventional medical treatment.Nonetheless, a number of current investigations have demonstrated the effectiveness and safety of EVT in VBAO patients.Therefore, in the actual
BibTeX
@article{zhang2024commentary,
  author = {Jinping Zhang and Haitao Li and Zunlu Zhang and Mingzhe Hu and Bingchen Li},
  title = {{Commentary on ‘Prognostic factors for acute vertebrobasilar artery occlusion-reperfusion: a multicenter retrospective cohort study’}},
  journal = {International Journal of Surgery},
  year = {2024},
  doi = {10.1097/js9.0000000000001668},
}
Figure